Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia (VADYSMA)

November 8, 2026 updated by: Prof. Jan Martinek, MD, PhD, AGAF, Institute for Clinical and Experimental Medicine

A Prospective Pilot Trial of Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia (VADYSMA Trial)

Laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. However, any type of fundoplication may be accompanied by adverse events. Postfundoplication dysphagia (PFD) may hamper results of anti-reflux surgery. Endoscopic pneumatic dilation has been considered as the first line treatment option for persistent PFD. However, studies have not confirmed its effectiveness in this indication. Peroral endoscopic myotomy (POEM) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory PFD and some patients achieved significant treatment success. The investigators plan to perform a prospective international cohort multicenter study assessing the efficacy of POEM in patients with persistent and severe PFD.

Study Overview

Status

Recruiting

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Brno, Czechia, 60200
        • Recruiting
        • St. Anne's University Hospital Brno, Czech Republic
        • Contact:
        • Contact:
      • Trnava, Slovakia, 91701
        • Not yet recruiting
        • University Hospital Trnava
        • Contact:
        • Contact:
    • Slovakia
      • Martin, Slovakia, Slovakia, 03601
        • Recruiting
        • Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin,
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients after laparoscopic fundoplication procedure by Nissen (total, 360°), Dor (anterior, 180°) or Toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment.
  2. Refractory (> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline.
  3. X-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and GEJ; b.) partial/total stagnation of the contrast solution above the GEJ
  4. Endoluminal planimetry: EGJ-DI < 3 mm2/mmHg (with 40ml)
  5. Age above 18 years
  6. Signed informed consent form

Exclusion Criteria:

  1. No previous attempt with at least one prokinetic drug
  2. Previous esophageal myotomy (open, laparoscopic or endoscopic)
  3. Primary esophageal motility disorder (achalasia etc.)
  4. Active erosive esophagitis
  5. Active peptic ulcer disease
  6. Esophageal stricture (peptic, malignant, other)
  7. Partial or complete supradiaphragmatic migration of the wrap and/or stomach (Hinder Type III - IV), Large hiatal hernia more than 5 cm
  8. Known eosinophilic esophagitis
  9. Severe coagulopathy
  10. Esophageal or gastric varices
  11. Advanced liver cirrhosis (Child B or Child C)
  12. Pregnancy or puerperium
  13. Malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment
  14. Any other condition, which in the opinion of the investigator would interfere with study requirements
  15. Known gastroparesis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: POEM arm

Patients, who will undergo peroral endoscopic myotomy for postfundoplication dysphagia

All procedures will be performed by an experienced endoscopist, with a sufficient experience in "third space" endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficacy POEM in patients with postfundoplication dysfagia
Time Frame: 6 months

The primary outcome will be proportion of patients with treatment success defined as Eckardt score ≤ 2 and its decrease by at least 1 point after POEM at 6 months

6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Eckardt score
Time Frame: At baseline, 3, 6 and 12 months

The Eckardt score is the grading system used for the evaluation of severity of symptoms in patients with esophageal achalasia. Four symptoms are assessed (dysphagia, regurgitation, chest pain and weight loss) and their severity ranges from 0 (no symptom) to 3 (with every meal). Total score is their sum and ranges from 0 to 12

At baseline, 3, 6 and 12 months
Mellow - Pinkas score
Time Frame: At baseline, 3, 6 and 12 months

The Mellow - Pinkas score is used to assess dysphagia grade before and after the interventions. Total score ranges from 0 to 3 (0 = able to eat normal diet, 1 = able to swallow some solid foods, 2 = able to swallow only semi solid foods, 3 = able to swallow liquids only)

At baseline, 3, 6 and 12 months
PAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)
Time Frame: At baseline, 3, 6 and 12 months

The PAGI-QoL questionnaire contains of 30 items with five subscales: (1) daily activities; (2) clothing; (3) diet/food habits; (4) relationship; and (5) psychological well-being and distress. Each item is scored on a 6-point Likert scale, with response options ranging from 0 (none) to 5 (severe problem all of the time). Subscale scores are calculated by averaging the item responses. A total score is calculated by averaging subscale scores. Higher score means impairment in quality of life.

At baseline, 3, 6 and 12 months
GERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)
Time Frame: At baseline, 3, 6 and 12 months

The GERD-HRQL questionnaire was developed and validated to measure changes of typical GERD symptoms such as heartburn and regurgitation in response to surgical or medical treatment. Higher (greater) possible score means worst symptoms - ranging from 0 to 75.

At baseline, 3, 6 and 12 months
Integrated Relaxation Pressure (IRP)
Time Frame: At baseline, at 6 months

High resolution manometry - Median IRP recorded from 10 supine swallows, measured in mmHg. A value >15 mmHg indicates EGJ outflow obstruction.

At baseline, at 6 months
Endoluminal planimetry (Endoflip)
Time Frame: At baseline, ať 6 months

Pyloric distensibility measured by impedance planimetry (EndoFLIP device)

At baseline, ať 6 months
Esophagogram
Time Frame: At baseline, at 6 months

Esophagogram provides valuable information of the fundoplication, better appreciate a paraesophageal hernia and information on esophageal emptying.

Patients will be advised overnight fasting prior to timed barium esophagogram. A contrast agent (e.g. barium, usually 100 to 250 mL) is ingested orally within 15-20 seconds. Left posterior oblique X-ray will be taken 2 and 5 minutes after contrast agent ingestion. Maximum esophageal width and column hights will be recorded at 2 and 5 minutes.

At baseline, at 6 months
Eckardt score
Time Frame: At baseline, 3 and 12 months

The Eckardt score is used to assess the severity of achalasia symptoms. It is based on the four main symptoms of achalasia: dysphagia, regurgitation, chest pain and weight loss. Each symptom has four levels of severity: none = 0 point, occasional = 1 point, daily = 2 points, each meal = 3 points. The sum of the points gives the final score. Final score scale: 0 (best) - 12 (worst). Treatment success is defined as a decrease of Eckardt score by at least 1 point and an overall Eckardt score ≤ 2.

At baseline, 3 and 12 months
GERD
Time Frame: At baseline, 3, 6 and 12 months

Presence of reflux esophagitis based on endoscopy findings.

At baseline, 3, 6 and 12 months
Esophageal 24h-Hour pH metry
Time Frame: At 3 months after procedure

An esophageal pH test measures how often stomach acid enters to the esophagus. It also measures how long the acid stays there. The test involves placing a catheter into the esophagus. The catheter or device will measure an acid level (known as pH level) for 24 hours. Post-POEM Esophageal acid exposure (DeMeester score, proportion of time with pH below 4)After

At 3 months after procedure
PPI/H2 antagonists
Time Frame: At baseline, 3, 6 and 12 months

PPI's and/or H2 antagonists use before and after procedure (POEM).

At baseline, 3, 6 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2025

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

February 10, 2025

First Submitted That Met QC Criteria

March 6, 2025

First Posted (Actual)

March 12, 2025

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 8, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe